🇺🇸 FDA
Patent

US 12065498

Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

granted A61KA61K2039/5156A61K2039/5158

Quick answer

US patent 12065498 (Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same) held by Cell Design Labs, Inc. expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cell Design Labs, Inc.
Grant date
Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/5156, A61K2039/5158, A61K2239/29, A61K2239/48